Here are four things to know:
1. The KUR-113 device is intended for use with lumbar intervertebral body fusion devices.
2. The device comprises a natural fibrin-based healing matrix with an immobilized targeted bone growthfactor. It is designed to directly apply onto and around an intervertebral body fusion device as a gel.
3. KUR-133 will be combined with an interbody spacer device in the upcoming clinical trial for Kuros Biosciences’ interbody spinal fusion product.
4. Kuros Biosciences plans to feature the spinal fusion product at the North American Association of Spinal Surgeons’ orthobiologics course in Chicago, Oct. 19.
More articles on biologics:
3 things to know about Reinvent Biologics
‘A new dawn’ for orthopedics: Dr. Jason Arora on the promise of biologics
Fujifilm, Cynata to collaborate on stem cell therapy trials for transplant patients: 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.